Eleven Biotherapeutics to Present at Upcoming Investor Conferences in March
March 01 2017 - 8:00AM
Business Wire
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage
clinical oncology company advancing a broad pipeline of novel
product candidates based on its Targeting Protein Therapeutics
(TPTs) platform, today announced that Stephen HurlPy, President and
Chief Executive Officer, will present a company overview at two
upcoming investor conferences. Details are as follows:
Cowen and Company 37th Annual Health
Care Conference
Date: Wednesday, March 8, 2017
Time: 8:00 a.m. ET
Location: Boston, MA
29th Annual Roth Conference
Date: Tuesday, March 14, 2017
Time: 2:30 p.m. PT (5:30 p.m. ET)
Location: Dana Point, CA
A live webcast of both events will be available under “Events
& Presentations” in the Investors & Media section of
Eleven's website, www.elevenbio.com. An archived replay of the
presentations will be available on the Company's website
approximately one hour after the live events and will be available
for 90 days following the presentations.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late-stage clinical oncology
company advancing a broad pipeline of novel product candidates
based upon the Company's targeted protein therapeutics (TPTs)
platform. The Company's TPTs incorporate a tumor-targeting antibody
fragment and a protein cytotoxic payload into a single protein
molecule in order to achieve focused tumor cell killing. The
Company believes its TPT approach offers significant advantages in
treating cancer over existing antibody drug conjugate technologies.
The Company believes its TPTs provide effective tumor targeting
with broader cancer cell-killing properties than are achievable
with small molecule payloads that require tumor cell proliferation
and face multi-drug resistance mechanisms. Additionally, the
Company believes that its TPT's cancer cell-killing properties
promote an anti-tumor immune response that will potentially combine
well with immune oncology drugs such as checkpoint inhibitors. For
more information please refer to the Company's website at
www.elevenbio.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170301005255/en/
Stern Investor RelationsHannah
Deresiewiczhannahd@sternir.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2023 to Apr 2024
